May 20, 2022
Ono Pharmaceutical said on May 18 that its PD-1 inhibitor Opdivo (nivolumab) grabbed an additional nod in Taiwan for untreated advanced renal cell carcinoma (RCC) in combination with the kinase inhibitor cabozantinib. The approval, granted to Ono’s Taiwanese subsidiary on...read more